GlobeNewswire

GridGain® Experts Share Hands-On Advice About How In-Memory Computing Can Make New or Existing Applications 1,000x Faster and Scalable to Petabytes

Dela

FOSTER CITY, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- GridGain® Systems, provider of enterprise-grade in-memory computing solutions based on Apache® Ignite(TM), today highlighted its ongoing commitment to helping businesses of all sizes understand how in-memory computing can help them address the speed and scalability requirements of modern, data-intensive applications.

"The demand for information about in-memory computing continues to soar as more enterprises recognize their need for real-time performance as they create or scale out applications related to digital transformation, omnichannel marketing and regulatory compliance initiatives," said Terry Erisman, Vice President of Marketing at GridGain. "Our in-memory computing experts enjoy sharing their practical knowledge about how to apply distributed in-memory computing technology to a range of data-intensive use cases."

To start the year, GridGain Founder and CTO Nikita Ivanov spoke at Persistent Memory Summit 2018, where he served as a panelist on "Hype to Reality, a Panel Discussion with Leaders of Real World Persistent Memory Applications."

Over the coming months, GridGain will host or participate in the following conferences, webinars and meetups:

Webinars

Workshops

  • Workshop: In-Memory Computing Essentials for Data Scientists, February 15, 2018 - In this hands-on workshop by GridGain Technology Evangelist Akmal Chaudhri, attendees will be introduced to the fundamental capabilities of in-memory computing platforms that boost highly-loaded applications, research projects, risk analysis and fraud detection tasks by storing and processing massive amounts of data in memory and on disk across a cluster of machines.
  • Amsterdam Java User Group, March 8, 2018 - GridGain Technology Evangelist Akmal Chaudhri will lead a workshop titled "In-Memory Computing Essentials for Java Developers."

Conferences

  • DeveloperWeek 2018 - February 3-7, 2018 - On Wednesday, February 7, GridGain Product Manager and Apache Ignite PMC Chairman Denis Magda will present "Apache Ignite Service Grid: Foundation of Your Microservices-Based Solution." 

Meetups

  • In-Memory in Manhattan! January 25, 2018 - GridGain Technology Evangelist Akmal Chaudhri will present "Building Consistent and Highly Available Distributed Systems with Apache Ignite and GridGain."
  • Los Angeles Kubernetes Meetup, January 31, 2018 - GridGain Solution Architect Dani Traphagen will present "Deploy like a Boss: Using Kubernetes and Apache Ignite!"
  • Big Data Application Meetup, January 31, 2018 - GridGain Product Manager and Apache Ignite PMC Chairman Denis Magda will present "Apache Spark and Apache Ignite: Where Fast Data Meets the IoT." 
  • The New York City Java Meetup Group, January 31, 2018 - GridGain Senior Solutions Architect Fotios Filacouris will present "Java and In-Memory Computing: Apache Ignite."
  • London In-Memory Computing Meetup, February 7, 2018 - GridGain Technology Evangelist Akmal Chaudhri will present "Building Consistent and Highly Available Distributed Systems with Apache Ignite and GridGain."
  • The Boston MySQL Meetup Group, February 12, 2018 - GridGain Senior Solutions Architect Fotios Filacouris will present "Turbocharge your MySQL Queries In-Memory with Apache Ignite." 
  • The Boston Java Meetup Group, February 13, 2018 - GridGain Senior Solutions Architect Fotios Filacouris will present "Java and In-Memory Computing: Apache Ignite."
  • Symbion IoT Meetup, February 14, 2018 - GridGain Technology Evangelist Akmal Chaudhri will present "Apache Ignite: The In-Memory Hammer in Your Data Science Toolkit." 
  • Sydney Cassandra Users, February 13, 2018 - Rachel Pedreschi, GridGain's Principal Solutions Architect, will present "Ignite your Cassandra Love Story: Caching Cassandra with Apache Ignite."
  • San Francisco Kubernetes Meetup , February 15, 2010 - GridGain Product Manager and Apache Ignite PMC Chairman Denis Magda will present "Distributed Database DevOps Dilemmas? Kubernetes to the Rescue!"
  • Berlin Kubernetes Meetup, February 21, 2018 - GridGain Technology Evangelist Akmal Chaudhri will present "Distributed Database DevOps Dilemmas? Kubernetes to the Rescue!"
  • Big Data, Berlin, February 22, 2018 - GridGain Technology Evangelist Akmal Chaudhri will present "Apache Ignite: The In-Memory Hammer in Your Data Science Toolkit."
  • Amsterdam Java User Group, March 7, 2018 - GridGain Technology Evangelist Akmal Chaudhri will present "Catch An Intro to the Java-Powered Apache Ignite - Memory-Centric Distributed Platform."

             
About GridGain® Systems
GridGain Systems is revolutionizing real-time data access and processing by offering enterprise-grade in-memory computing solutions built on Apache® Ignite(TM). GridGain solutions are used by global enterprises in financial, software, ecommerce, retail, online business services, healthcare, telecom and other major sectors. GridGain solutions connect data stores (SQL, NoSQL, and Apache® Hadoop®) with cloud-scale applications and enable massive data throughput and ultra-low latencies across a scalable, distributed cluster of commodity servers. GridGain is the most comprehensive, enterprise-grade in-memory computing platform for high volume ACID transactions, real-time analytics, and hybrid transactional/analytical processing. For more information, visit gridgain.com.

CONTACT:
Terry Erisman
GridGain Systems
terisman@gridgain.com
(650) 241-2281

GridGain is a trademark or registered trademark of GridGain Systems, Inc. Apache,  Apache CassandraCassandra, Apache Hadoop, Hadoop, Apache Ignite, and Ignite are trademarks of The Apache Software Foundation. All other product and company names herein may be trademarks of their registered owners.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: GridGain Systems via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Arcomas CFO lämnar bolaget21.2.2019 23:50:00Pressmeddelande

Arcomas CFO, AnnaPia Johansson har valt att avsluta sin tjänst för nya utmaningar utanför Arcoma. AnnaPia arbetar oförändrat vidare i sin nuvarande tjänst fram till augusti månad eller tills att en ersättare har rekryterats. "Jag vill tacka AnnaPia för hennes ambitiösa arbete för Arcoma och samtidigt önska henne lycka i framtida utmaningar " säger Jesper Söderqvist, VD Arcoma. Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade i hela världen. Arcoma är listat på Nasdaq First North. Certified Advi

Corline Biomedical AB offentliggör bokslutskommuniké för räkenskapsåret 201821.2.2019 08:45:00Pressmeddelande

Corline Biomedical AB ("Corline") publicerar härmed bokslutskommuniké för det fjärde kvartalet och räkenskapsåret 2018. Nedan följer en kort sammanfattning. Fullständig bokslutskommuniké finns tillgänglig på Corlines hemsida (www.corline.se) samt som bifogad fil. VD Henrik Nittmar kommenterar "2018 blev ett genombrottsår för Corline då bolaget gick från preklinisk till klinisk fas i utvecklingen av Renaparin® i och med att RENAPAIR 01-studien öppnade för rekrytering. Nu koncentrerar vi utvecklingsresurserna på att planera inför den värdehöjande fas 2- och fas 3-utvecklingen. Jämfört med branschkollegor har Corline en särskilt gynnsam position i och med att bolaget står på flera ben och parallellt arbetar mot lansering tillsammans med kunder inom medicinteknikområdet. Ett spännande 2019 stundar." Väsentliga händelser under det fjärde kvartalet 2018 Den vetenskapliga tidskriften Transplantation publicerar resultat från den prekliniska utvecklingen av Renaparin®. Här visas i stordjursmode

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum